InVivoMAb anti-human pan-Glypican
BE0412
ApplicationsFunctional Assay, Flow Cytometry, ImmunoPrecipitation, ELISA, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-human pan-Glypican
- Delivery Days Customer7
- ApplicationsFunctional Assay, Flow Cytometry, ImmunoPrecipitation, ELISA, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDHS20
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostHuman
- IsotypeIgG1
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Luo Y, Hao H, Wang Z, et al. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis. bioRxiv. 2023,:pii: 2023.07.26.550758. doi: 10.1101/2023.07.26.550758.Read this paper
- Cui XY, Tjønnfjord GE, Kanse SM, et al. Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Sci Rep. 2021,11(1):5127. doi: 10.1038/s41598-021-84695-8Read this paper
- Dubey R, van Kerkhof P, Jordens I, et al. R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling. Elife. 2020,9. doi: 10.7554/eLife.54469Read this paper
- Gao W, Xu Y, Liu J, et al. Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Sci Rep. 2016,6:26245. doi: 10.1038/srep26245Read this paper
- Gao W, Kim H, Ho M. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One. 2015,10(9):e0137664. doi: 10.1371/journal.pone.0137664Read this paper
- Gao W, Tang Z, Zhang YF, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015,6:6536. doi: 10.1038/ncomms7536Read this paper
- Gao W, Kim H, Feng M, et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology. 2014,60(2):576-87. doi: 10.1002/hep.26996Read this paper